DK108589D0 - Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer - Google Patents

Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Info

Publication number
DK108589D0
DK108589D0 DK108589A DK108589A DK108589D0 DK 108589 D0 DK108589 D0 DK 108589D0 DK 108589 A DK108589 A DK 108589A DK 108589 A DK108589 A DK 108589A DK 108589 D0 DK108589 D0 DK 108589D0
Authority
DK
Denmark
Prior art keywords
antibodies
chimerary
humant
dna sequences
sequences coding
Prior art date
Application number
DK108589A
Other languages
English (en)
Other versions
DK108589A (da
Inventor
Dennis J Carlo
Gary Samuel David
Mary Jaqueline Johnson
Catherine Brautigam Beidler
James Richard Ludwig
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of DK108589D0 publication Critical patent/DK108589D0/da
Publication of DK108589A publication Critical patent/DK108589A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK108589A 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer DK108589A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16585688A 1988-03-09 1988-03-09
US27257788A 1988-11-17 1988-11-17

Publications (2)

Publication Number Publication Date
DK108589D0 true DK108589D0 (da) 1989-03-07
DK108589A DK108589A (da) 1989-09-22

Family

ID=26861757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK108589A DK108589A (da) 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Country Status (5)

Country Link
EP (1) EP0332424A3 (da)
JP (1) JPH029371A (da)
AU (1) AU618990B2 (da)
DK (1) DK108589A (da)
IL (1) IL89489A0 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
AU634314B2 (en) * 1989-11-13 1993-02-18 Green Cross Corporation, The Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ATE171472T1 (de) * 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6380979B1 (en) * 1996-07-02 2002-04-30 Matsushita Electric Industrial Co., Ltd. Scanning line converting circuit and interpolation coefficient generating circuit
JP2003520195A (ja) 1999-05-14 2003-07-02 イムクローン システムズ インコーポレイティド 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
IL152825A (en) 2000-05-16 2009-07-20 Univ Jefferson Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
DK2308507T3 (da) 2002-07-19 2015-04-20 Beth Israel Hospital Fremgangsmåder til behandling af præeklampsi
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
DK1784220T3 (da) 2004-08-26 2018-03-19 Univ Western Ontario Bakterielle mål til opnåelse af jern
CA2581336C (en) 2004-09-24 2022-10-04 S. Ananth Karumanchi Diagnosis of pregnancy-related hypertensive disorder by measurement of soluble endoglin
CN102397542B (zh) 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
AU2007274738B2 (en) 2006-07-18 2013-11-28 Sanofi-Aventis Antagonist antibody against EphA2 for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2009222998B2 (en) 2008-03-12 2013-05-23 Imclone Llc Anti-TYRP1 antibodies
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
WO2011022472A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
WO2011062560A1 (en) * 2009-11-19 2011-05-26 National University Of Singapore Method for producing t cell receptor-like monoclonal antibodies and uses thereof
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
CN102844050B (zh) 2010-02-19 2019-02-05 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
DE202014008375U1 (de) 2014-10-18 2015-10-21 Reinz-Dichtungs-Gmbh Seperatorplatte und elektrochemisches System
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL89490A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Chimeric antibodies directed against metal chelates
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies

Also Published As

Publication number Publication date
AU618990B2 (en) 1992-01-16
AU3107289A (en) 1989-09-14
JPH029371A (ja) 1990-01-12
IL89489A0 (en) 1989-09-10
DK108589A (da) 1989-09-22
EP0332424A3 (en) 1991-07-03
EP0332424A2 (en) 1989-09-13

Similar Documents

Publication Publication Date Title
DK108589A (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer
DK108189A (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen og metal-chelater samt dna-sekvenser, der koder for saadanne antistoffer
DK296189A (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
DE68924227T2 (de) DNA-Fragment.
DE68911113T2 (de) Kodiereinrichtung.
NO891818D0 (no) T4-reseptor-protein, relaterte dna-sekvenser samt fremstilling derav.
DE68907519D1 (de) Biosensoren.
DE3879452T2 (de) Chimaere antikoerper.
DE68922772T2 (de) Verfahren zur Zeichenkettenermittlung.
DK38989A (da) Dna-sekvens
NO892294L (no) Polypeptidforbindelser.
FI894658A0 (fi) Vattenhaltiga foerbraenningskatalysatorer samt braenslen.
NO881384D0 (no) Peptider.
DK639988D0 (da) Peptider samt anvendelse deraf.
DE68914933D1 (de) Abrasionsprüfgeräte.
FI861691A (fi) En ny tumoerassocierad antigen.
FI893279A (fi) Antivirusmedel samt kompositioner innehaollande desamma.
DE68908528D1 (de) Testmethode.
FI893450A (fi) Modifierade proteiner.
DK324287D0 (da) Antistof mod koensspecifikt antigen
DE68921683D1 (de) Selbstblockierender Testträger.
DK108489A (da) Chimere antistoffer rettet mod metal-chelater af edta-derivater, samt dna-sekvenser, der koder for saadanne antistoffer
DK578189D0 (da) Dna-sekvens
DK448687D0 (da) Dna, der koder for et virusantigen
DE68913971T2 (de) Ferromagnetische materialien.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment